Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2026 | $29.00 | Neutral → Buy | BofA Securities |
| 2/24/2026 | $33.00 | Outperform | Wolfe Research |
| 2/23/2026 | $35.00 | Neutral → Outperform | Mizuho |
| 10/21/2025 | $33.00 | Buy | Citigroup |
| 5/21/2025 | $35.00 | Hold → Buy | Deutsche Bank |
| 2/11/2025 | $22.00 | Hold | Deutsche Bank |
| 1/3/2025 | $23.00 → $20.00 | Buy → Neutral | Guggenheim |
| 10/10/2024 | Mkt Perform | Raymond James |
-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome and highlights the importance of flexible, patient-centered treatment approaches Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and onl
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert
SCHEDULE 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity
BofA Securities upgraded ACADIA Pharmaceuticals from Neutral to Buy and set a new price target of $29.00
Wolfe Research initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $33.00
Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Konstantina ("Tina") Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia's business development and corporate strategy and serve as a member of the Company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. "Tina brings a wealth of experience in global business development and strategic partnerships that will be instrumental as we continue to expand our pipeline and pursue high-impact growth opportunities," said Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals. "Her leadership and deep i
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia's digital transformation including technology, data and AI strategy and will serve as a member of the company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. "We are thrilled to welcome Scott to Acadia," said Catherine Owen Adams. "Scott's extensive leadership in digital transformation, AI-driven innovation, and global IT operations across leading biopharmaceutical companies makes him an ideal fit for our organization. His proven ability to scale digital
Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until May 24, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive
- Third quarter total revenues of $278.6 million, up 11% year-over-year - Narrowing and raising high end of NUPLAZID® net product sales guidance to $685 to $695 million - Updating DAYBUE® net product sales guidance to $385 to $400 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2025. "Acadia delivered another strong quarter, generating total revenue of $278.6 million," said Catherine Owen Adams, Chief Executive Officer. "NUPLAZID achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. DAYBUE delivered $101.1 million in sales, driven by t
Company to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until February 5, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)